The intersectoral platform is part of the National Pandemic Cohort Network (NAPKON) andwill be used to provide a comprehensive and harmonized collection of data and biomaterialfor researchers from national consortia, pharmaceutical companies and for participationin international research collaborations for the purpose of studying COVID-19 disease andfuture pandemics.
The intersectoral platform is part of the National Pandemic Cohort Network (NAPKON),
which, together and in interaction with other components of the National Research Network
of University Medicine on COVID-19 (NUM), provides the essential basis for the successful
understanding and thus combating pandemics using the example of coronavirus disease 2019
(COVID-19). NAPKON represents a sustainable, integrative and comprehensive concept that
provides benefits for society as a whole in defending against and coping with pandemics,
especially at the level of public health care, in hospital and patient management and
from the individual patient's perspective.
The intersectoral platform records data and biomaterial of severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2)-infected patients through a network of
university clinics, hospitals at all levels of care, general practitioners and specialist
practices with appropriate study experience and infrastructure. The longitudinal
phenotyping programme tracks patients for up to one year and collects detailed and
harmonized clinical data as well as biomaterial. Follow-up data is enriched by
patient-reported outcomes (PROM) and recruitment is intensified by focusing on hot-spot
regions. Mobile study teams are used to reach, among others, long-term care and
rehabilitation facilities, thus mapping all structural elements of the German care
network.
The primary aim of the intersectoral platform is to provide a comprehensive and
harmonized collection of data and biomaterial for researchers from national consortia,
pharmaceutical companies and for participation in international research collaborations
for the purpose of studying COVID-19 disease and future pandemics.
Other: Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are
recruited from the general population (POP), and on subjects with acute SARS-CoV-2
infections recruited (II) in university hospital high-care settings or (III) general
health care.
Inclusion Criteria:
1. Age ≥18 years
2. Compliance with the case definition (a-c):
1. Polymerase chain reaction (PCR) or rapid test diagnosis from nasopharynx,
bronchoalveolar lavage, oropharynx, stool and/or blood
2. or a combination of:
- negative molecular detection of SARS-CoV-2 AND
- characteristic radiological findings AND
- respiratory tract infection AND
- absence of a more likely cause of disease, in particular other chronic
lung diseases AND
- Negative test for influenza
3. or (control group) a combination of:
- negative molecular detection of SARS-CoV-2 AND
- respiratory tract infection AND
- absence of a more likely cause of disease, in particular other chronic
lung diseases AND
- attempt of pathogen identification from respiratory material with at least
culture and influenza test
3. The baseline visit needs to be performed a maximum of 7 days (168h) after sampling
and 4 days (96h) after the case definition is available.
4. Signed informed consent
Exclusion Criteria:
1. Age <18 years
2. Paediatric patients will not be included at the beginning of the study (amendment in
preparation).
RWTH Aachen
Aachen, Germany
University Hospital Augsburg
Augsburg, Germany
Charité Berlin
Berlin, Germany
Klinikum Bielefeld
Bielefeld, Germany
University Hospital Ruhr-University Bochum
Bochum, Germany
University Hospital Bonn
Bonn, Germany
University Hospital Cologne
Cologne, Germany
University Hospital Carl Gustav Carus Dresden
Dresden, Germany
University Hospital Dusseldorf
Dusseldorf, Germany
University Hospital Erlangen
Erlangen, Germany
University Hospital Essen
Essen, Germany
Johann Wolfgang Goethe University
Frankfurt am Main, Germany
University Hospital Freiburg
Freiburg, Germany
University Hospital Greifswald
Greifswald, Germany
University Hospital Göttingen
Göttingen, Germany
University Hospital Halle
Halle/Saale, Germany
University Hospital Hamburg-Eppendorf
Hamburg, Germany
University Hospital MMH Hannover
Hannover, Germany
University Hospital Heidelberg
Heidelberg, Germany
University Hospital UKS Homburg
Homburg, Germany
University Hospital Jena
Jena, Germany
University Hospital UKSH Schleswig-Holstein
Kiel, Germany
University Hospital Leipzig
Leipzig, Germany
University Hospital UKSH Schleswig-Holstein
Lübeck, Germany
University Hospital Mannheim
Mannheim, Germany
University Hospital Giessen/Marburg
Marburg, Germany
University Hospital LMU Munich
Munich, Germany
University Hospital TUM Munich
Munich, Germany
University Hospital Münster
Münster, Germany
Klinikum Oldenburg
Oldenburg, Germany
University Hospital Regensburg
Regensburg, Germany
University Hospital Tübingen
Tübingen, Germany
University Hospital Ulm
Ulm, Germany
University Hospital Würzburg
Würzburg, Germany
Jörg J Vehreschild, Prof.
+49 221 478-88794
Janne.Vehreschild@kgu.de
Jörg J Vehreschild, Prof., Principal Investigator
Johann Wolfgang Goethe-Universität Frankfurt am Main